Implantable Cardioverter Defibrillators (ICD)s are battery-powered devices placed under the skin for keeping a track of heart rate. It has been proved quite useful in preventing sudden death in patients suffering from sustained ventricular tachycardia or fibrillation. ICD holds a critical role in preventing cardiac arrest in high-risk patients who are more prone to life-threatening ventricular arrhythmias. In this process, ICD is connected through thin wires with the patient’s heart.
Get Free Sample Copy @ https://www.omrglobal.com/request-sample/implantable-cardioverter-defibrillators-market
The device delivers an electric shock to restore a normal heartbeat in case of an abnormal heart rhythm, if patient’s heart is beating chaotically and much too fast. Though ICDs have demonstrated clear life-saving benefits; concerns about patient acceptance along with psychological adjustment to the ICD have been the focus of much research.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/implantable-cardioverter-defibrillators-market
As per researchers, the Quality of Life (QoL) of ICD patients can be better than that of those taking anti-arrhythmic medications. Usually, ICDs are composed of an ICD generator and wires; the first component consists of a programmable software, computer chip or circuitry with RAM (memory), a capacitor and a battery. There are two type of ICDS namely, Transvenous (TV) patients are vulnerable to complications such as fractures, which can turn to inappropriate therapy and infections. Additionally, a device-related infection rate generally varies between 0.67% and 1.49% over a 3 to 12-month follow-up. Moreover, mechanical lead failures can arouse from hardware malfunction, which can further result in inappropriate shocks, over sensing, and inability to deliver appropriate therapy. Furthermore, long-term lead failure rates up to 20% have been reported with Transvenous defibrillators.
Subcutaneous ICD is alternative novel technology used to limit complications associated with transvenous implantable cardioverter-defibrillator. Traditionally, S-ICD was used in patients with difficult venous access. As a result, congenital heart disease patients with venous anomalies are considered good candidates for S-ICD. Additionally, patients who are expected to outlive the life expectancy of their TV leads and requiring device extractions later in life can be ideal for S-ICD. It may also be used in patients with channelopathies or those who undergo renal replacement therapies and require chronic venous access.
Market Segmentation
By Product
- Transvenous Implantable CardioverterDefibrillator (T-ICDS)
- Subcutaneous Implantable CardioverterDefibrillator (S-ICDS)
By End-Users
- Hospitals
- Diagnostic Centers
- Ambulatory Service
- Homecare
Regional Analysis
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
Rest of the World
Company Profiles
- Abbott Laboratories, Inc.
- Biotronik SE & Co. KG
- Cintas Corp.
- Defibtech, LLC
- General Electric Co.
- Koninklijke Philips N.V.
- LivaNova PLC
- Medtronic PLC
- Nihon Kohden Corp.
- Stryker Corp.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
